Skip to content

The effect of the test food (low dose) intake on cognitive functioning

The effect of the test food (low dose) intake on cognitive functioning - The effect of the test food (low dose) intake on cognitive functioning

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000061545
Enrollment
100
Registered
2026-05-13
Start date
2026-06-22
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Continuous intake of food containing rice protein hydrolysate for 12 weeks Continuous intake of placebo foods for 12 weeks

Sponsors

HUMA R&D CORP
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Helthy Japanese males and females who are between 50 and 69 years of age at the time of written informed consent. 2.Subjects who are aware of cognitive decline. 3.Subjects whose scoring of MMSE-J is 24 or more at screening. 4.Subjects who are fully explained the purpose and details of the study, have ability to consent, are volunteering to participate in the study with a full understanding of the explanation, and have consented to participate in the study in writing.

Exclusion criteria

Exclusion criteria: 1.Subjects who have been diagnosed with dementia by a physician. 2.Subjects receiving medication or outpatient treatment for a serious disease. 3.Subjects receiving exercise or diet therapy under the supervision of a physician. 4.Subjects who may develop an allergy to the ingredient of the test food. 5.Subjects with current or previous history of drug dependence or alcohol dependence. 6.Subjects who are currently seeing a doctor for the treatment of a psychiatric disorder (e.g., depression) and/or sleep disorder (e.g., insomnia, sleep apnea syndrome) or have previous history of a psychiatric disorder. 7.Subjects who have extremely irregular life rhythms due to night work, shift work, etc. 8.Subjects whose eating, sleeping, and other habits are extremely irregular. 9.Subjects who are having a very unbalanced diet. 10.Heavy users of alcohol (the mean consumption of pure alcohol is 60 g/day or more) 11.Subjects with smoking habits. 12.Subjects who regularly consume large amounts of caffeinated beverages (400 mg of caffeine or more per day) 13.Subjects with current or previous history of a brain disease, malignancy, immunological disease, diabetes mellitus, hepatic disease (hepatitis), renal disease, cardiac disease, thyroid disease, adrenal disease, metabolic disease, or other serious diseases. 14.Subjects who use or are unable to stop using health foods, supplements (e.g., ginkgo biloba extract, DHA, EPA, and GABA), and drugs that may affect cognitive functioning. 15.Subjects who regularly consume sardines, mackerels, skippers, or other similar fishes as well as foods containing these fishes. 16.Subjects with color blindness. 17.Subjects who usually use devices, equipment, and applications that may affect cognitive functions. (e.g., brain training puzzles, brain training games)

Design outcomes

Primary

MeasureTime frame
Cognitrax

Secondary

MeasureTime frame
Trail Making Test,QOL survey (SF-36v2 Japanese version)

Countries

Japan

Contacts

Public ContactHiroyuki Miyazawa

HUMA R&D CORP Clinical Development Department

rd@huma-rd.co.jp03-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026